Prognostic significance of CXCL5 expression in cancer patients: a meta-analysis

Hu, Binwu; Fan, Huiqian; Lv, Xiao; Chen, Songfeng; Shao, Zhimin

doi:10.1186/s12935-018-0562-7

Cited by 42 publications

(28 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In postoperative survival analysis of patients after complete pancreatic cancer resection, the mean survival time of CXCL5 expression group is 25.5 months, shorter than the negative groups [31]. CXCL5 overexpression was also reported to be inversely associated with overall survival of patients with intrahepatic cholangiocarcinoma and hepatocellular carcinoma [5].…”

Section: Cxcl5 As a Potential Prognostic Biomarkermentioning

confidence: 96%

“…The results of multiple logistic regression analysis showed that CXCL5 expression level is a significant risk factor for N phase (N2, N3) in gastric cancer but is not associated with T phase [64]. According a recent meta-analysis, CXCL5 expression level in tumor tissues was found to act as an independent prognostic factor for survival in cancer patients [5]. In postoperative survival analysis of patients after complete pancreatic cancer resection, the mean survival time of CXCL5 expression group is 25.5 months, shorter than the negative groups [31].…”

Section: Cxcl5 As a Potential Prognostic Biomarkermentioning

confidence: 99%

“…The regulatory complexity of the interaction between tumors cells and host cells in TME affects the clinical application of many therapeutic targets [4]. In recent years, studies on C-X-C motif chemokine ligand 5 (CXCL5) in tumor progression have proved that it can be used as a potential indicator of tumor prognosis [5]. Previous studies have reported that CXCL5/C-X-C motif chemokine receptor 2 (CXCR2) axis can stimulate tumor growth and angiogenesis, and promote the infiltration and activation of host cells [6].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target

Zhang

Wang

Sun

et al. 2020

Cancer Communications

147

View full text Add to dashboard Cite

The components of the tumor microenvironment (TME) in solid tumors, especially chemokines, are currently attracting much attention from scientists. C-X-C motif chemokine ligand 5 (CXCL5) is one of the important chemokines in TME. Overexpression of CXCL5 is closely related to the survival time, recurrence and metastasis of cancer patients. In TME, CXCL5 binds to its receptors, such as C-X-C motif chemokine receptor 2 (CXCR2), to participate in the recruitment of immune cells and promote angiogenesis, tumor growth, and metastasis. The CXCL5/CXCR2 axis can act as a bridge between tumor cells and host cells in TME. Blocking the transmission of CXCL5/CXCR2 signals can increase the sensitivity and effectiveness of immunotherapy and slow down tumor progression. CXCL5 and CXCR2 are also regarded as biomarkers for predicting prognosis and molecular targets for customizing the treatment. In this review, we summarized the current literature regarding the biological functions and clinical significance of CXCL5/CXCR2 axis in TME. The possibility to use CXCL5 and CXCR2 as potential prognostic biomarkers and therapeutic targets in cancer is also discussed

show abstract

Section: Cxcl5 As a Potential Prognostic Biomarkermentioning

confidence: 96%

Section: Cxcl5 As a Potential Prognostic Biomarkermentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target

Zhang

Wang

Sun

et al. 2020

Cancer Communications

147

View full text Add to dashboard Cite

show abstract

“…CXCL5 is a proangiogenic chemokine and a strong attractant for granulocytes and is secreted by various immune-and specific non-immune cells. In the context of cancer, CXCL5 has also been associated with late-stage disease and promotion of metastases [55][56][57]. Since the CXCL5 gene is not among the LATE genes, caution is advised regarding cause and effect of high CXCL5 plasma levels in subjects with LOY.…”

Section: Loy In Blood Is Associated With Changes In the Plasma Proteomementioning

confidence: 99%

Immune cells lacking Y chromosome have widespread dysregulation of autosomal genes

Dumanski

Halvardson

Davies

et al. 2019

Preprint

View full text Add to dashboard Cite

Mosaic loss of chromosome Y (LOY) in blood is linked to increased risk for morbidity and mortality in men. LOY is the most common acquired mutation and is associated with diseases such as cancer and Alzhemer's disease. We studied DNA, RNA and proteins in bulk, sorted-and single-cells in vivo and in vitro. We show that Alzheimer's disease and prostate cancer patients had more LOY in NK cells and CD4+ T-lymphocytes, respectively. Furthermore, gene expression was profoundly altered in cells with LOY in a pleiotropic fashion and autosomal genes important for normal immune cell functions showed LOY associated transcriptional effect. Proteomic analysis also indicated that LOY leaves a footprint in the plasma proteome. We provide the first mechanistic explanation for the associations between LOY in blood and risk for disease in other organs.Recent epidemiological analyses have challenged the view that LOY in blood cells is phenotypically neutral. Studies have identified increased risks for men with LOY in connection with all-cause mortality [8,9], Alzheimer's disease [10], various forms of cancer [8,[11][12][13], autoimmune conditions [14,15], age-related macular degeneration [16], cardiovascular disease [17], type 2 diabetes and obesity [9]. Furthermore, it has been known for centuries that males have a shorter life expectancy [18][19][20]. Hence, LOY as a male specific risk factor, showing reproducible associations with various common disorders, could help explaining this difference.LOY in blood is the most frequent post-zygotic mutation, detectable in 20% of the UK Biobank male population [21], reaching 40% in 80 years old males [22], and 57% in 93 years old males [23]. Furthermore, LOY is not restricted to the hematopoietic system, since it has also been described in other non-cancerous tissues, although with much lower frequencies [17,23]. Our understanding of why LOY occurs is also limited. Strong associations with age and smoking have been reported [8,10,24,25] and these factors are related to a continuously increasing mutational load throughout the genome in all somatic cells, eventually also affecting genes that are responsible for correct segregation of chromosomes. Inherited genetic predisposition for LOY has also been described [21,25,26].It is not known whether associations between LOY and increased risks for disease represent causal relationships, and if so, what the underlying mechanisms could be. The challenge that we address here is to move from epidemiological associations to mechanistic explanations on multiple levels of analysis such as DNA, mRNA and proteins. Specifically, we studied: (i) frequency of LOY in subsets of leukocytes from patients with prostate cancer (PC), Alzheimer's disease (AD) as well as controls; (ii) changes in transcriptomes of single cells and cellular subsets in bulk; and (iii) alterations of plasma protein levels in men with LOY. Different distribution of LOY in six types of sorted leukocytes among men with AD and PCStudies of associations between LOY and various outcomes hav...

show abstract

“…It is also involved in cancer proliferation in different tissues [29][30][31]. Its clinical value for cancer prognosis is also recently becoming very significant [32,33].…”

Section: Introductionmentioning

confidence: 99%

CXCL5 Modified Nanoparticle Surface Improves CXCR2+ Cell Selective Internalization

Cagliani

Gatto

Cibecchini

et al. 2019

Cells

View full text Add to dashboard Cite

Driving nanomaterials to specific cell populations is still a major challenge for different biomedical applications. Several strategies to improve cell binding and uptake have been tried thus far by intrinsic material modifications or decoration with active molecules onto their surface. In the present work, we covalently bound the chemokine CXCL5 on fluorescently labeled amino-functionalized SiO2 nanoparticles to precisely targeting CXCR2+ immune cells. We synthesized and precisely characterized the physicochemical features of the modified particles. The presence of CXCL5 on the surface was detected by z-potential variation and CXCL5-specific electron microscopy immunogold labeling. CXCL5-amino SiO2 nanoparticle cell binding and internalization performances were analyzed in CXCR2+ THP-1 cells by flow cytometry and confocal microscopy. We showed improved internalization of the chemokine modified particles in the absence or the presence of serum. This internalization was reduced by cell pre-treatment with free CXCL5. Furthermore, we demonstrated CXCR2+ cell preferential targeting by comparing particle uptake in THP-1 vs. low-CXCR2 expressing HeLa cells. Our results provide the proof of principle that chemokine decorated nanomaterials enhance uptake and allow precise cell subset localization. The possibility to aim at selective chemokine receptor-expressing cells can be beneficial for the diverse pathological conditions involving immune reactions.

show abstract

Prognostic significance of CXCL5 expression in cancer patients: a meta-analysis

Cited by 42 publications

References 48 publications

CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target

CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target

Immune cells lacking Y chromosome have widespread dysregulation of autosomal genes

CXCL5 Modified Nanoparticle Surface Improves CXCR2+ Cell Selective Internalization

Contact Info

Product

Resources

About